Chemical-Pharmaceutical Application of Carnitine Palmitoyltransferase-2 (CPT-II) Through Regulating Mitochondrial Against Cancer Tumoric Cells
Yazarlar (4)
Prof. Dr. Majıd MONAJJEMI Islamic Azad University, Central Tehran Branch, İran
Dr. Öğr. Üyesi Fatemeh MOLLAAMIN Kastamonu Üniversitesi, Türkiye
Samira Mohammadi
Islamic Azad University, Central Tehran Branch, İran
Sara Shahriari Islamic Azad University, Central Tehran Branch, İran
Makale Türü Açık Erişim Özgün Makale (SCOPUS dergilerinde yayınlanan tam makale)
Dergi Adı Revista Colombiana De Ciencias Quimico Farmaceuticas Colombia
Dergi ISSN 0034-7418 Scopus Dergi
Makale Dili İngilizce Basım Tarihi 01-2024
Cilt / Sayı / Sayfa 53 / 3 / 777–803 DOI 10.15446/rcciquifa.v53n3.119213
Özet
Background: Carnitine palmitoyltransferase II deficiency is an inherited disorder of long-chain fatty acid oxidation characterized by hypoketotic hypoglycemia, cardiomyopathy, seizures, muscle pain and weakness, and myoglobin. Individuals with carnitine palmitoyltransferase II deficiency have a defect in the production of the enzyme carnitine palmitoyltransferase-II, which plays an important role in fatty acid oxidation. Signs and symptoms of carnitine palmitoyltransferase II deficiency are due to the buildup of fatty acids and long-chain acyl-carnitine as well as reduced energy production in cells. Carnitine palmitoyltransferase II deficiency is an auto-somal recessive disease caused by mutations in the CPT2 gene. During changing Nonalcoholic fatty liver disease (NAFLD) to the cirrhosis, the probability of cancer is high that should be considered as a dangerous situation. Methods: SDS-PAGE system of polyacrylamide gel electrophoresis through analytical method for sepa-rating charged molecules in mitochondrial mixtures according to their molecular mass in the presence of electrical fields was used. The Invitrogen® Bright Imaging (IBI) system provides was applied for the imaging and analysis of protein imprints. Results: Since currently no effective treatment for CPT-II deficiency, prevention of liver failure is a proper way of treatment through controlling mitochondria without affecting CPT-II potency. We discussed about the severe infantile hepatocardiac muscular position of CPT II deficiency affects the liver heart, and muscles. Conclusions: Through this work, we discussed and characterized the pathophysiological function in several tissues such as liver, Kidney cancers.
Anahtar Kelimeler
Carcinoma hepatocelular | carcinoma hepatocelular | CPT-I | CPT-I | CPT-I | CPT-II | CPT-II | CPT-II | Cáncer de hígado | Câncer de fígado | Doença hepática gordurosa não alcoólica | Enfermedad del hígado graso no alcohólico | Falência renal | Hepatocellular carcinoma | Insuficiencia renal | Kidny failure | Liver cancer | Nonalcoholic fatty liver disease | SDS-PAGE system | Sistema SDS-PAGE | Sistema SDS-PAGE